Document Detail

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.
MedLine Citation:
PMID:  16641937     Owner:  NLM     Status:  MEDLINE    
Clinical studies suggest that adjunct galantamine may improve negative and cognitive symptoms in schizophrenia. These symptoms may be related to impaired dopaminergic function in the prefrontal cortex. Indeed, galantamine has been shown to increase dopamine release in vitro. Galantamine is an allosteric modulator of nicotinic acetylcholine receptors (nAChRs) and, at higher doses, an acetylcholine esterase (AChE) inhibitor. We have previously shown that nicotine, through stimulation of nAChRs in the ventral tegmental area (VTA), activates midbrain dopamine neurons and, hence, potentiation of these receptors could be an additional mechanism by which galantamine can activate dopaminergic pathways. Therefore, the effects of galantamine (0.01-1.0 mg/kg s.c.) on dopamine cell firing were tested in anaesthetized rats. Already at a low dose, unlikely to result in significant AchE inhibition, galantamine increased firing activity of dopaminergic cells in the VTA. The effect of galantamine was prevented by the nAChR antagonist mecamylamine (1.0 mg/kg s.c.), but not the muscarinic receptor antagonist scopolamine (0.1 mg/kg s.c.), and it was not mimicked by the selective AChE inhibitor donepezil (1.0 mg/kg s.c.). Our data thus indicate that galantamine increases dopaminergic activity through allosteric potentiation of nAChRs. Galantamine's effect was also prevented by the alpha7 nAChR antagonist methyllycaconitine (6.0 mg/kg i.p.) as well as the N-methyl-D-aspartate antagonist CGP39551 (2.5 mg/kg s.c.), indicating a mechanism involving presynaptic facilitation of glutamate release. In parallel microdialysis experiments, galantamine was found to increase extracellular levels of dopamine in the medial prefrontal cortex. These results may have bearing on the enhancement of negative and cognitive symptoms in schizophrenia.
Björn Schilström; Vladimir B Ivanov; Charlotte Wiker; Torgny H Svensson
Related Documents :
19498417 - Mysterious alpha6-containing nachrs: function, pharmacology, and pathophysiology.
10373437 - Nicotinic acetylcholine receptors assembled from the alpha7 and beta3 subunits.
15050617 - Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation ag...
15569257 - Functional characterization of mouse alpha4beta2 nicotinic acetylcholine receptors stab...
6135797 - Alpha and beta-adrenergic mediation of membrane potential changes and metabolism in rat...
17613937 - Neuropeptide s: a novel modulator of stress and arousal.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-04-26
Journal Detail:
Title:  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology     Volume:  32     ISSN:  0893-133X     ISO Abbreviation:  Neuropsychopharmacology     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-14     Completed Date:  2007-02-09     Revised Date:  2011-05-18    
Medline Journal Info:
Nlm Unique ID:  8904907     Medline TA:  Neuropsychopharmacology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  43-53     Citation Subset:  IM    
Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
2-Amino-5-phosphonovalerate / analogs & derivatives,  pharmacology
Action Potentials / drug effects
Analysis of Variance
Cholinesterase Inhibitors / pharmacology*
Dopamine / metabolism*
Dose-Response Relationship, Drug
Excitatory Amino Acid Antagonists / pharmacology
Galantamine / pharmacology*
Indans / pharmacology
Mecamylamine / pharmacology
Microdialysis / methods
Neurons / drug effects,  physiology
Nicotinic Antagonists / pharmacology
Piperidines / pharmacology
Prefrontal Cortex / cytology,  drug effects
Rats, Sprague-Dawley
Receptors, Nicotinic / physiology*
Synaptic Transmission / drug effects*
Ventral Tegmental Area / cytology
Reg. No./Substance:
0/Cholinesterase Inhibitors; 0/Excitatory Amino Acid Antagonists; 0/Indans; 0/Nicotinic Antagonists; 0/Piperidines; 0/Receptors, Nicotinic; 120011-70-3/donepezil; 127910-32-1/CGP 39551; 357-70-0/Galantamine; 60-40-2/Mecamylamine; 76726-92-6/2-Amino-5-phosphonovalerate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepres...
Next Document:  Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward...